Skip to main content
S&P 5007,631.19+1.05%DOW51,782.71+0.62%NASDAQ26,380.94+1.55%BTC$76,845.00+1.55%ETH$2,470.93+3.49%GOLD$4,400.80+0.30%OIL$102.02-0.40%
Smart Investors Daily
Codexis, Inc. logo

NASDAQ · CDXS

Codexis, Inc.

Healthcare · Biotechnology

$1.34

Down-$0.05 (-3.69%)

Updated Sep 17, 2026, 5:30 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
144.21M
P/E ratio
-2.4
Dividend yield
0.00%
52-week range
$0.96 – $2.98
Volume
954.28K
Avg. volume
910.65K

Price performance

CDXS price history

1M range · 20 trading sessions · Daily adjusted prices

CDXS closed at $1.34 after 20 trading sessions, down 16.25% for the selected period.

Last close
$1.34
Period change
-16.25%
Period low
$1.34
Period high
$1.70
Daily close
View OHLC price history
CDXS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$1.42$1.43$1.34$1.34954.28K
Sep 15, 2026$1.47$1.49$1.38$1.40608.73K
Sep 14, 2026$1.45$1.50$1.43$1.48477.57K
Sep 11, 2026$1.45$1.475$1.43$1.465505.06K
Sep 10, 2026$1.42$1.45$1.405$1.44467.31K
Sep 9, 2026$1.43$1.45$1.42$1.43513.3K
Sep 8, 2026$1.48$1.50$1.425$1.43655.4K
Sep 4, 2026$1.43$1.4832$1.43$1.46757.84K
Sep 3, 2026$1.48$1.4999$1.41$1.421.01M
Sep 2, 2026$1.52$1.59$1.47$1.475998.04K
Sep 1, 2026$1.67$1.695$1.50$1.511.07M
Aug 31, 2026$1.59$1.715$1.56$1.701.39M
Aug 28, 2026$1.66$1.68$1.58$1.59634.65K
Aug 27, 2026$1.64$1.66$1.60$1.66591.84K
Aug 26, 2026$1.68$1.70$1.61$1.65559.98K
Aug 25, 2026$1.67$1.72$1.661$1.68811.02K
Aug 24, 2026$1.69$1.765$1.631$1.661.36M
Aug 21, 2026$1.60$1.695$1.576$1.671.26M
Aug 20, 2026$1.60$1.649$1.56$1.581.28M
Aug 19, 2026$1.51$1.65$1.51$1.601.98M

Latest CDXS news

The latest Smart Investors Daily articles mentioning CDXS.

Stock researchCompany · Overview

CDXS research

Overview

Company profile and research snapshot.

Company profile

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.00
Implied upside
—
Analysts
13
CDXS recent ratings
DateFirmRatingTarget
Aug 17, 2026Piper SandlerOverweight—
Nov 22, 2024Cantor FitzgeraldOverweight—
Nov 15, 2024Cantor FitzgeraldOverweight—
Nov 4, 2024BenchmarkHold—
Sep 20, 2024Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

Codexis to Participate in Cantor Global Healthcare Conference 2026

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York. Management will participate in a fireside chat on Thursday, September 10, 2026, at 9:45 am ET. A live webcast of the event will be available in the Investor Relatio

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By